Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Appoints Four Directors for Pharmacogenomics

Premium

CAMBRIDGE, Mass.--Variagenics, a privately held venture-backed drug discovery technology company here, announced the appointment of four pharmacogenomics directors.

Mark Adams, previously the bioinformatics director for Alphagene, will be Variagenics' director of bioinformatics. Patrice Rioux, formerly medical director for Biogen, is Variagenics' new director of clinical pharmacogenomics. Troy Norris, also formerly of Biogen, where he was responsible for research and development program prioritization, is now senior director of business development for pharmacogenomics. And Andrew Ferrie joins Variagenics as director of variance detection from his former position as gene discovery manager at Human Genome Sciences.

"Variagenics' core competency is in the rapid discovery and analysis of genetic variation using our proprietary Variance Scanning and Variance Imaging technologies," said Fred Ledley, Variagenics' CEO. The appointments move the company toward its goal of applying genetic variation to the discovery and development of new pharmaceuitcal products, he said.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.